retatrutide type 2 diabetes trial results Eli Lilly just announced striking Phase 3 for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide, a TRIPLE agonist (GLP1,
Description
GLP-1 also blocks glucagon secretion
Theres a possible increase in the risk of gallbladder disease in people taking semaglutide for more than six months
doi: 10.1002/oby.22359
Is compounded semaglutide as good as Wegovy
both treatments can support meaningful, sustainable weight loss , but they differ in how they act, likely outcomes, and practical considerations like cost and coverage
Some patients report that taking their injection at night allows them to sleep through the initial period when side effects might occur
